Is Cipher Pharmaceuticals Inc. (CPH) halal?
Cipher Pharmaceuticals Inc. (TSX: CPH) is a Mississauga-based specialty pharmaceutical company — a permissible business — with essentially no interest-bearing debt (only US$367K of lease obligations, about 0.1% of market cap) and Q2 2026 interest income of about 0.12% of revenue. Both ratio gates clear, so this screener gives CPH a PASS. Data from Q2 2026 results, screened September 30, 2026.
The two-gate Shariah screen
Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).
Gate one: the business — specialty pharmaceuticals
Cipher Pharmaceuticals (TSX: CPH; OTCQX: CPHRF), based in Mississauga, Ontario, is a specialty pharmaceutical company. It acquires, develops, and markets prescription products in Canada, the U.S., and South America. Its commercial portfolio is led by Natroba (spinosad, an anti-parasitic for head lice) in the U.S. and Epuris (isotretinoin, an acne treatment holding about 47.1% of the Canadian isotretinoin market as of June 30, 2026) in Canada, plus licensing revenue from partners. Revenue comes from medicine sales and product licensing — no alcohol, tobacco, gambling, conventional finance or insurance, pork, adult entertainment, weapons, or cannabis business lines. The business gate passes.
Gate two: the ratios — all gates clear
- Interest-bearing debt: Cipher reported nil long-term debt at June 30, 2026 — it repaid the US$5M outstanding balance on its revolving credit facility on March 30, 2026 (a US$65M revolver plus a US$25M accordion remain undrawn). Its only interest-bearing obligations are lease obligations: US$242K current + US$125K non-current = US$367K.
- Market cap: 25,391,322 shares outstanding (April 24, 2026) × C$13.89 (TSX close, September 25, 2026) = about C$352.7M (roughly US$247M).
- Debt ÷ market cap: US$367K ÷ ≈ US$247M = about 0.1% — under the ~33% AAOIFI ceiling.
- Interest income (Q2 2026 income statement): US$15K ÷ Q2 2026 revenue of US$12,067K = about 0.12% — under the ~5% AAOIFI ceiling (the disclosed line is net "Interest (income) expense" of US$(15K)).
- Cash: US$9.1M of cash at June 30, 2026 — about 3.7% of market cap, comfortably under the ~33% cash-plus-securities ceiling.
Every ratio gate clears with wide margin.
What other screeners say
- Musaffa: rates CPH.TO halal as of September 2026 (AAOIFI methodology; no ratio breakdown published) — agreeing with this screener's PASS.
- Zoya: no public rating page found for CPH. ShariaPortfolio: no public rating page found for CPH.
The bottom line
This screener gives Cipher Pharmaceuticals Inc. (TSX: CPH) a PASS. A permissible specialty-pharmaceutical business, effectively zero interest-bearing debt (leases only, about 0.1% of market cap), and interest income at about 0.12% of revenue — all gates clear. Snapshot dated September 30, 2026; re-checked quarterly after earnings.
Sources
- Cipher Pharmaceuticals Q2 2026 results press release (August 11, 2026) — condensed consolidated statements of income and financial position (tables 1–3).
- Normal Course Issuer Bid announcement (May 1, 2026): 25,391,322 common shares outstanding as of April 24, 2026.
- Market data: TSX:CPH closed C$13.89 on September 25, 2026.
- Musaffa CPH.TO rating page (September 2026).
Related screeners
Frequently asked questions
Is Cipher Pharmaceuticals (CPH) halal?
Our screener gives Cipher Pharmaceuticals Inc. a PASS screening result. Cipher is a specialty pharmaceutical company (Natroba anti-parasitic in the U.S., Epuris isotretinoin in Canada, plus licensing) with no prohibited business lines, interest-bearing debt of only US$0.367M in lease obligations (about 0.1% of market cap, under the 33% AAOIFI threshold), and Q2 2026 interest income of US$15K equal to 0.12% of revenue (under the 5% threshold).
How much debt does Cipher Pharmaceuticals have?
Essentially none. Cipher repaid the US$5M outstanding balance on its revolving credit facility on March 30, 2026 and reported nil long-term debt at June 30, 2026. Its only interest-bearing obligations are lease obligations of US$242K current and US$125K non-current, totalling US$367K. A US$65M revolver plus a US$25M accordion remain undrawn.
Does Cipher Pharmaceuticals earn interest income?
Very little. Cipher's Q2 2026 income statement shows an "Interest (income) expense" line of US$(15K) — i.e. net interest income of US$15,000 — against Q2 revenue of US$12,067K. That is 0.12% of revenue, under the 5% AAOIFI threshold.
What does Musaffa say about Cipher Pharmaceuticals?
Musaffa rates CPH.TO halal as of September 2026 (AAOIFI methodology; no ratio breakdown published), which agrees with this screener's PASS. We found no public Zoya or ShariaPortfolio rating pages for CPH.
Is Cipher Pharmaceuticals being acquired or delisted?
No takeover bid or delisting announcement. Notable: the TSX accepted a normal course issuer bid in May 2026 (up to 1,490,343 shares for cancellation by May 4, 2027); Cipher executed a letter of intent with the pan-Canadian Pharmaceutical Alliance in July 2026 expanding public reimbursement of Epuris; and it launched a Natroba stocking program across U.S. Walmart stores in Q3 2026.